Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumabReport as inadecuate




Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab - Download this document for free, or read online. Document in PDF available to download.

Rheumatology International

, Volume 32, Issue 12, pp 4041–4045

First Online: 11 September 2011Received: 04 May 2011Accepted: 21 August 2011

Abstract

Regarding the pathobiology of rheumatoid arthritis, oxidative stress induced by reactive oxygen species is an important mechanism that underlies destructive and proliferative synovitis. Abundant amounts of reactive oxygen species have been detected in the synovial fluid of inflamed rheumatoid joints. It is reported that drugs that block tumor necrosis factor-α reduce the oxidative stress marker levels in patients with rheumatoid arthritis. In this study, we measured reactive oxygen species using a free radical analytical system in patients with rheumatoid arthritis treated with disease-modifying antirheumatic drugs, tumor necrosis factor-α-blocking drugs infliximab, etanercept, and an interleukin-6-blocking drug tocilizumab. The serum level of oxidative stress was drastically low in patients with rheumatoid arthritis treated with tocilizumab, suggesting that interleukin-6 blocking therapy reduces not only joint damage, but also vascular degeneration in patients with rheumatoid arthritis. We believe that such a drastic effect would reduce the incidence of cardiovascular events and mortality in patients with rheumatoid arthritis.

KeywordsRheumatoid arthritis Oxidative stress Reactive oxygen species IL-6 Tocilizumab  Download fulltext PDF



Author: Makoto Hirao - Naomi Yamasaki - Hiroki Oze - Kosuke Ebina - Akihide Nampei - Yoshitaka Kawato - Kenrin Shi - Hideki Yoshik

Source: https://link.springer.com/







Related documents